Hormonal
Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.
If you have type 2 diabetes and existing heart disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications, taken as a weekly injection, have been proven to significantly lower your risk of heart attacks, strokes, and death compared to standard treatments. This is a critical step for protecting your heart and kidneys.
In a meta-analysis of these eight clinical trials, GLP1 receptor agonists significantly reduced MACEs (hazard ratio 0.86, 95% confidence interval 0.80-0.93), cardiovascular death (hazard ratio 0.87, 95% confidence interval 0.80-0.94), and all-cause death (hazard ratio 0.82, 95% confidence interval 0.82-0.94).
Why this rating
Based on a meta-analysis of eight randomized clinical trials involving thousands of patients.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →